Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Open Access
- 1 August 2022
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (1) , 27-35
Abstract
Purpose: Acromegaly and neuroendocrine tumors are rare diseases that, under certain conditions, can be treated with somatostatin analogs. The aim was to determine the prescription patterns of somatostatin analogs in a group of patients with acromegaly and neuroendocrine tumors affiliated with the Colombian Health System. Methods: A retrospective study. A cohort of patients from a drug dispensing database that collected all prescriptions of long-acting somatostatin analogs (octreotide, lanreotide, pasireotide). Sociodemographic variables, clinical variables (diagnosis and comorbidities) and pharmacological therapy variables (dose, changes, persistence of use, comedications) were considered. Results: A total of 213 patients were identified, including 139 (65.3%) with acromegaly and 74 (34.7%) with neuroendocrine tumors. There was a predominance of women (58.7%) and a mean age of 59.7 ± 14.5 years. The most commonly used medications were lanreotide autogel (n = 107; 50.2%), octreotide LAR (n = 102; 47.9%) and pasireotide LAR (n = 4; 1.9%). During follow-up, 11.3% of patients experienced modifications of therapy, with a mean duration from the beginning of treatment to the change in medication of 25 ± 15.9 months. A total of 48.9% of the patients with acromegaly and 87.1% of individuals with neuroendocrine tumors received maximum approved doses of the drug. Conclusion: Patients with acromegaly and neuroendocrine tumors in Colombia are mainly women and are most frequently treated with lanreotide autogel for acromegaly and with octreotide LAR for neuroendocrine tumors. In addition, a high proportion are managed with maximum doses of long-acting somatostatin analogs.Keywords
Funding Information
- Sanofi Colombia S.A and IPSEN Export Latin America (E003183552)
- Technological University of Pereira
This publication has 35 references indexed in Scilit:
- Somatostatin analogs as a first-line treatment in acromegalyCurrent Opinion in Endocrinology, Diabetes and Obesity, 2012
- Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?European Journal of Endocrinology, 2012
- Clinical, quality of life, and economic value of acromegaly disease controlPituitary, 2011
- The Epidemiology of Gastroenteropancreatic Neuroendocrine TumorsEndocrinology and Metabolism Clinics of North America, 2011
- Current management practices for acromegaly: an international surveyPituitary, 2010
- Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under‐recognized and under‐diagnosedClinical Endocrinology, 2010
- Acromegaly pathogenesis and treatmentJournal of Clinical Investigation, 2009
- Management of acromegaly in Latin America: expert panel recommendationsPituitary, 2009
- AcromegalyBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- Midgut neuroendocrine tumours with liver metastases: results of the UKINETS studyEndocrine-Related Cancer, 2009